In hypertensive crisis with malignant hypertension, which of the following is an appropriate agent?

In hypertensive crisis with malignant hypertension, which of the following is an appropriate agent?

• A. Hydralazine
• B. ACE inhibitors
• C. Furosemide
• D. Nicardipine or labetalol

Answer: (D)

In a hypertensive crisis with malignant hypertension, the goal is rapid but controlled lowering of blood pressure using intravenous, titratable therapy. The best options are IV nicardipine or IV labetalol because they can be started quickly and adjusted continuously to achieve a safe reduction (about 20–25% in the first hour, then gradual improvement). Nicardipine lowers vascular resistance smoothly without causing undue reflex changes, while labetalol provides both alpha and beta blockade to reduce BP with less reflex tachycardia. Other choices are less ideal for this scenario: hydralazine can give unpredictable and sometimes excessive BP drops with reflex tachycardia, ACE inhibitors may be slower to act and carry renal risks, and furosemide alone addresses volume but does not reliably lower BP quickly enough in malignant hypertension. So the most appropriate approach is an IV, titratable agent like nicardipine or labetalol for careful BP control.

In a hypertensive crisis with malignant hypertension, the goal is rapid but controlled lowering of blood pressure using intravenous, titratable therapy. The best options are IV nicardipine or IV labetalol because they can be started quickly and adjusted continuously to achieve a safe reduction (about 20–25% in the first hour, then gradual improvement). Nicardipine lowers vascular resistance smoothly without causing undue reflex changes, while labetalol provides both alpha and beta blockade to reduce BP with less reflex tachycardia. Other choices are less ideal for this scenario: hydralazine can give unpredictable and sometimes excessive BP drops with reflex tachycardia, ACE inhibitors may be slower to act and carry renal risks, and furosemide alone addresses volume but does not reliably lower BP quickly enough in malignant hypertension. So the most appropriate approach is an IV, titratable agent like nicardipine or labetalol for careful BP control.